 | | Vol. 6.32 – 2 September, 2022 |
| |
|
|
| The authors studied the regulatory crosstalk between the two pathways that control the transition from hepatosteatosis to steatohepatitis.
[Cell Metabolism] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists investigated the role of RIPK3 in modulating mitochondria function, coupled with lipid droplet architecture in non-alcoholic fatty acid liver disease.
[Hepatology] |
|
|
|
| The authors showed that p53 expression increased gradually and reached maximal levels around eight days when laminin α4, α5, β2, β1, and γ1 subunit levels also reached a maximum during hepatic progenitor cell activation and expansion.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Using cultured cells, researchers found that Arid1a loss caused cellular proliferation, escape from cell-cycle control, senescence, and widespread changes in chromatin structure.
[Cell Reports] |
|
|
|
| To understand the role of hepatocellular PROM1 in liver fibrosis, global and liver-specific Prom1-deficient mice were analyzed after bile duct ligation. Investigators found that PROM1 was upregulated in the plasma membrane of fibrotic hepatocytes.
[Experimental and Molecular Medicine] |
|
|
|
| Researchers generated porcine intrahepatic cholangiocyte organoids from adult stem cells and demonstrated that these cultures remained stable over multiple passages whilst retaining the ability to differentiate into hepatocyte- and cholangiocyte-like cells.
[Journal of Cellular and Molecular Medicine] |
|
|
|
| The authors found that corosolic acid could inhibit glutathione synthesis (GSH) via HERPUD1, decreasing the cellular GSH level and causing liver cancer cells to become more sensitive to ferroptosis.
[Cell Death Discovery] |
|
|
|
| Investigators reported that the long non-coding RNA SNHG6 increased progression from non-alcoholic fatty liver disease to HCC by modulating cholesterol-induced mTORC1 activation.
[Nature Metabolism] |
|
|
|
|
|
| The authors review the existing literature on racial and ethnic, gender, and socioeconomic disparities in chronic liver diseases using a social determinants of health framework to better understand how social and structural factors cause health disparities and affect chronic liver disease outcomes.
[Hepatology] |
|
|
|
| Scientists summarize the currently available liver miRNA profiling studies in people with various stages of NAFLD, and describe the mechanistic role of three of the most extensively studied miRNA species.
[Molecular Metabolism] |
|
|
|
|
| Madrigal Pharmaceuticals, Inc. announced initiation of the study of resmetirom, which will noninvasively measure progression to liver decompensation events in approximately 700 patients with compensated NASH cirrhosis.
[Madrigal Pharmaceuticals] |
|
|
|
| LyGenesis plans to inject liver cells from a donor into the lymph nodes of sick recipients, which could give rise to entirely new miniature organs.
[LyGenesis (MIT Technology Review)] |
|
|
|
|
| February 5 – 8, 2022
Keystone, Colorado, United States |
|
|
|
|
|
| | STEMCELL Technologies, Inc. – Vancouver, British Columbia, Canada |
|
|
|
| | BenevolentAI – Cambridge, UK |
|
|
|
|
| | Newcastle University – Newcastle Upon Tyne, England, United Kingdom |
|
|
|
| | University of North Carolina at Greensboro – Kannapolis, North Carolina, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
